Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 12/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 9/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 9/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7200244 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1KDM4EALDH1A1 | |
| SCHEMBL73904 | 0.83 | CHRM3 (0.85) | CHRM3CHRM2CHRM1KDM4EALDH1A1 | |
| SCHEMBL4668972 | 0.75 | CHRM3 (0.80) | CHRM3CHRM2CHRM1 | |
| SCHEMBL13875521 | 0.74 | CHRM3 (0.59) | CHRM3CHRM2CHRM1KDM4EALDH1A1 | |
| SCHEMBL5532368 | 0.74 | CHRM1 (0.59) | CHRM3CHRM2CHRM1KDM4EALDH1A1 | |
| SCHEMBL2821129 | 0.74 | CHRM2 (1.00) | CHRM3CHRM2CHRM1CHRNA7 | |
| SCHEMBL2819759 | 0.74 | CHRM2 (1.00) | CHRM3CHRM2CHRM1CHRNA7 | |
| SCHEMBL2819221 | 0.74 | CHRM2 (1.00) | CHRM3CHRM2CHRM1CHRNA7 | |
| SCHEMBL7514667 | 0.74 | CHRM3 (0.59) | CHRM3CHRM2CHRM1KDM4EALDH1A1 | |
| Bromide SCHEMBL4636715 | 0.74 | CHRM3 (0.81) | CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029728-A1 | PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-02-04 | — | — | US | disclosed |
| US-20080181970-A1 | Combinations of Vanadium with Antidiabetics for Glucose Metabolism Disorders | AKESIS PHARMACEUTICALS (US) | 2008-07-31 | — | — | US | disclosed |
| US-20070207218-A1 | Combinations of vanadium with antidiabetics for glucose metabolism disorders | AKESIS PHARMACEUTICALS (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070196512-A1 | Combinations of vanadium with antidiabetics for glucose metabolism disorders | AKESIS PHARMACEUTICALS (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070092584-A1 | Combinations of chromium with antidiabetics for glucose metabolism disorders | AKESIS PHARMACEUTICALS (US) | 2007-04-26 | — | — | US | disclosed |
| US-20060003981-A1 | Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders | FINE STUART A | 2006-01-05 | — | — | US | disclosed |
| US-20050233947-A1 | Combinations of chromium or vanadium with antidiabetics | FINE STUART A | 2005-10-20 | — | — | US | disclosed |
| US-20050203027-A1 | Inhibitors of dipeptidylpeptidase IV | TRUSTEES OF TUFTS COLLEGE (US) | 2005-09-15 | — | — | US | disclosed |
| US-20050187144-A1 | Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders | FINE STUART A (US) | 2005-08-25 | — | — | US | disclosed |
| US-20040228846-A1 | Methods and reagents for treating glucose metabolic disorders | CURIS, INC. | 2004-11-18 | — | — | US | disclosed |
| US-20030153509-A1 | Inhibiting the dipeptidylpeptidase proteolysis of Glucagon-like peptide, by administering a dipeptides consisting Pro-Pro, Ala-Pro, and (D)-Ala-(L)-Ala; treating metabolism disorders, diabetes, obesity, atherosclerosis | ARISAPH PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| US-6107499-A | FACILITATING THE TRANSPORT OF A NEUROTRANSMITTER ACROSS THE BLOOD BRAIN BARRIER BY ADMINISTERING THE DRUG, A NEUROTRANSMITTER SUCH AS DOPAMINE COVALENTLY COUPLED TO A SINGLE, STRAIGHT-CHAINED FATTY ACID CARRIER MOLECULE | NEUROMEDICA, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| US-5994392-A | PASSAGE OF DRUG THROUGH BLOOD BRAIN BARRIER | NEUROMEDICA, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| US-5712265-A | ANTIDIABETIC AGENTS AND METABOIC AGGENTS | THE GENERAL HOSPITAL CORPORATION (US) | 1998-01-27 | — | — | US | disclosed |
| EP-0764026-A4 | ADMINISTRATION OF PIRENZEPINE, METHYL SCOPOLAMINE AND OTHER MUSCARINIC RECEPTOR ANTAGONISTS FOR TREATMENT OF LIPID METABOLISM DISORDERS | ERGO SCIENCE INC (US) | 1997-12-29 | — | — | EP | disclosed |
| US-5700795-A | ADMINISTERING AT PREDETERMINED TIME TO DECREASE HYPERINSULINEMIA, HYPERGLYCEMIA, INSULIN RESISTANCE | THE GENERAL HOSPITAL CORPORATION (US) | 1997-12-23 | — | — | US | disclosed |
| US-5668155-A | ALTERING LIPID METABOLISM IN VERTEBRATES FOR REDUCTION OF FATS | THE GENERAL HOSPITAL CORPORATION (US) | 1997-09-16 | — | — | US | disclosed |
| EP-0764026-A1 | ADMINISTRATION OF PIRENZEPINE, METHYL SCOPOLAMINE AND OTHER MUSCARINIC RECEPTOR ANTAGONISTS FOR TREATMENT OF LIPID METABOLISM DISORDERS | ERGO SCIENCE INCORPORATED (US) | 1997-03-26 | — | — | EP | disclosed |
| WO-1995035110-A1 | ADMINISTRATION OF PIRENZEPINE, METHYL SCOPOLAMINE AND OTHER MUSCARINIC RECEPTOR ANTAGONISTS FOR TREATMENT OF LIPID METABOLISM DISORDERS | ERGO SCIENCE INCORPORATED (US) | 1995-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029728-A1 | PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE4C | CHRM3 345/4885CHRM2 648/4885CHRM1 674/4885 |
| US-20050203027-A1 | Inhibitors of dipeptidylpeptidase IV | DPP4, DPP3, DPP7 | CHRM3 3102/4885CHRM2 4292/4885CHRM1 3727/4885 |
| US-20030153509-A1 | Inhibiting the dipeptidylpeptidase proteolysis of Glucagon-like peptide, by administering a dipeptides consisting Pro-Pro, Ala-Pro, and (D)-Ala-(L)-Ala; treating metabolism disorders, diabetes, obesity, atherosclerosis | DPP4, ENPEP, PEPD | CHRM3 4291/4885CHRM2 4409/4885CHRM1 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.